Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Autor: Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Westdorp H; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Wimmers F; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Aarntzen EH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Duiveman-de Boer T; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., van de Rakt MW; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Scharenborg NM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., de Boer AJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Pots JM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Olde Nordkamp MA; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., van Oorschot TG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Tel J; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Winkels G; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany., Petry K; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany., Blokx WA; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands., Welzen ME; Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands., Mus RD; Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Croockewit SA; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands., Koornstra RH; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Jacobs JF; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands., Kelderman S; Department of Immunology, Netherlands Cancer Institute NKI-AVL, Amsterdam, the Netherlands., Blank CU; Department of Immunology, Netherlands Cancer Institute NKI-AVL, Amsterdam, the Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. jolanda.devries@radboudumc.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 May 01; Vol. 22 (9), pp. 2155-66. Date of Electronic Publication: 2015 Dec 28.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Autor: Bol KF; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands ; Medical Oncology; Radboud university medical centre ; Nijmegen, The Netherlands., Figdor CG; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., Aarntzen EH; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands ; Radiology and Nuclear Medicine; Radboud university medical centre ; Nijmegen, The Netherlands., Welzen ME; Pharmacy; Radboud university medical centre ; Nijmegen, The Netherlands., van Rossum MM; Dermatology; Radboud university medical centre ; Nijmegen, The Netherlands., Blokx WA; Pathology; Radboud university medical centre ; Nijmegen, The Netherlands., van de Rakt MW; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., Scharenborg NM; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., de Boer AJ; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., Pots JM; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., Olde Nordkamp MA; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., van Oorschot TG; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., Mus RD; Radiology and Nuclear Medicine; Radboud university medical centre ; Nijmegen, The Netherlands., Croockewit SA; Hematology; Radboud university medical centre ; Nijmegen, The Netherlands., Jacobs JF; Laboratory Medicine; Radboud university medical centre ; Nijmegen, The Netherlands., Schuler G; Department of Dermatology; University Hospital Erlangen ; Erlangen, Germany., Neyns B; Department of Medical Oncology; Vrije Universiteit Brussel ; Brussels, Belgium., Austyn JM; Nuffield Department of Surgical Sciences; John Radcliffe Hospital; University of Oxford ; Oxford, UK., Punt CJ; Department of Medical Oncology; Academic Medical Center ; Amsterdam, The Netherlands., Schreibelt G; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands., de Vries IJ; Department of Tumor Immunology (Radboud Institute for Molecular Life Sciences); Radboud university medical centre ; Nijmegen, The Netherlands ; Medical Oncology; Radboud university medical centre ; Nijmegen, The Netherlands.

Publikováno v: Oncoimmunology [Oncoimmunology] 2015 Apr 01; Vol. 4 (8), pp. e1019197. Date of Electronic Publication: 2015 Apr 01 (Print Publication: 2015).

A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease.

Autor: Welzen ME; Departments of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. R.Bruggemann@akf.umcn.nl, Brüggemann RJ, Van Den Berg JM, Voogt HW, Gilissen JH, Pajkrt D, Klein N, Burger DM, Warris A

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2011 Sep; Vol. 30 (9), pp. 794-7.